IMR Press / FBL / Volume 21 / Issue 4 / DOI: 10.2741/4414

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

Inflammasomes in non-alcoholic fatty liver disease

Show Less
1 Department of Immunobiology, Institute of Tissue Transplantation and Immunology, Jinan University, Guangzhou, 510632, China
2 National Key Disciplines for Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen, 518112, China
3 School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China
Academic Editor:Jia Xiao
Front. Biosci. (Landmark Ed) 2016, 21(4), 683–695;
Published: 1 January 2016
(This article belongs to the Special Issue Research update on liver Immunology)

Non-alcoholic fatty liver disease (NAFLD) is a leading liver disorder in the world. Inflammation is one of the most important pathological events during the development of NAFLD and also represents the hallmark between simple steatosis and non-alcoholic steatohepatitis (NASH). Inflammasomes are novel protein complex platforms assembled in response to pattern-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). Currently, there are several identified inflammasomes, including nod-like receptor protein (NLRP)-1, 2, 3, 6, 10, 12, NLRC4 and absent in melanoma 2 (AIM2) inflammasomes. In the liver, inflammasomes are primarily expressed in immune cells. However, increasing evidence suggests that their expressions in other types of cells in the liver are also present. In general, inflammasomes are up-regulated in various liver diseases. In NAFLD, it is reported that the levels of inflammasome components (e.g. NLRPs, caspase-1, IL-1β and IL-18) are elevated. Silence of these components attenuates hepatic injury. Collectively, the main purposes of this review are to examine the recent progress of hepatic inflammasome research and to discuss possible directions of therapeutic strategy and development against NAFLD.

Non-alcoholic Fatty Liver; Inflammasome
Metabolic Disorders
Back to top